Synthetic Approaches to Contemporary Drugs that Contain the Cyclopropyl Moiety

This manuscript is dedicated to Emeritus Professor Slovenko Polanc, Ph.D. (University of Ljubljana) on the occasion of his 72^nd birthday.

Abstract

The U.S. Food and Drug Administration approved 18 new drugs that incorporate the cyclopropyl structural motif in the time frame from 2012 to 2018. This review provides an overview of synthetic approaches to these drugs with emphasis on the construction of the cyclopropyl moiety or its incorporation into the key building blocks for assembly of the highlighted drugs. Based on the structural diversity of these drugs, synthetic approaches for the construction and introduction of the cyclopropyl moiety into their structure are diverse and include: cycloalkylation (double alkylation) of CH-acids, catalytic cyclopropanation of alkenes with diazo compounds, the Simmons–Smith reaction, the Corey–Chaykovsky reaction, the Kulinkovich reaction, the Horner–Wadsworth–Emmons reaction, and cycloaddition. In addition, the cyclopropyl structure was also introduced into the drug substance intermediates via simple cyclopropyl-moiety-containing building blocks, such as cyclopropylamine, cyclopropanesulfonamide, cyclopropanecarbonyl chloride, and cyclopropylmagnesium bromide.

1 Introduction

2 Synthesis of Recently Approved Cyclopropyl-Moiety-Containing Drugs

2.1 Cabozantinib

2.2 Trametinib

2.3 Simeprevir

2.4 Ledipasvir

2.5 Olaparib

2.6 Tasimelteon

2.7 Finafloxacin

2.8 Paritaprevir

2.9 Lenvatinib

2.10 Lumacaftor

2.11 Lesinurad

2.12 Grazoprevir

2.13 Glecaprevir

2.14 Ozenoxacin

2.15 Voxilaprevir

2.16 Naldemedine

2.17 Tezacaftor

2.18 Tecovirimat

3 Conclusion

Keywords

drugs - cyclopropyl moiety - total synthesis - asymmetric synthesis - catalysis

• References


For selected reviews and book chapters on the chemistry, steric properties and electronic properties of cyclopropanes, see:
• 1a de Meijere A. Angew. Chem., Int. Ed. Engl. 1979; 18: 809
• 1b Wiberg KB. Structures, Energies and Spectra of Cyclopropanes. In The Chemistry of the Cyclopropyl Group, Vol. 1. Patai S, Rappaport Z. Wiley; Chichester: 1987: 1
• 1c Tidwell TT. Conjugative and Substituent Properties of the Cyclopropyl Group. In The Chemistry of the Cyclopropyl Group, Vol. 1. Patai S, Rappaport Z. Wiley; Chichester: 1987: 565
• 1d Cremer D, Kraka E, Szabo KJ. General and Theoretical Aspects of the Cyclopropyl Group . In The Chemistry of the Cyclopropyl Group, Vol. 2. Patai S, Rappaport Z. Wiley; Chichester: 1995: 43
• 1e Cremer D, Childs RF, Kraka E. Cyclopropyl Homoconjugation, Homoaromaticity and Homoantiaromaticity—Theoretical Aspects and Analysis. In The Chemistry of the Cyclopropyl Group, Vol. 2. Patai S, Rappaport Z. Wiley; Chichester: 1995: 339
• 1f de Meijere A, Kozhushkov SI. Chem. Rev. 2000; 100: 93
• 1g de Meijere A, Kozhushkov SI, Schill H. Chem. Rev. 2006; 106: 4926
• 1h Craig AJ, Hawkins BC. Synthesis 2020; 52: 27

For selected reviews on synthetic methods that lead to cyclopropane derivatives, see:
• 2a Tsuji T, Nishida S. Preparation of Cyclopropyl Derivatives . In The Chemistry of the Cyclopropyl Group, Vol. 1. Patai S, Rappaport Z. Wiley; Chichester: 1987: 307
• 2b Salaün J. Chem. Rev. 1989; 89: 1247
• 2c Ohkita M, Nishida S, Tsuji T. Recent Advances in Synthesis of Cyclopropanes . In The Chemistry of the Cyclopropyl Group, Vol. 2. Patai S, Rappaport Z. Wiley; Chichester: 1995: 261
• 2d Lebel H, Marcoux J.-F, Molinaro C, Charette AB. Chem. Rev. 2003; 103: 977
• 2e Pietruszka J. Chem. Rev. 2003; 103: 1051
• 2f Gnad F, Reiser O. Chem. Rev. 2003; 103: 1603
• 2g Gagnon A, Duplessis M, Fader L. Org. Prep. Proced. Int. 2010; 42: 1
• 2h Charette AE, Lebel H, Roy M.-N. Asymmetric Cyclopropanation and Aziridination Reactions . In Copper-Catalyzed Asymmetric Synthesis . Alexakis A, Krause N, Woodward S. Wiley-VCH; Weinheim: 2014: 203
• 2i Chanthamath S, Iwasa S. Acc. Chem. Res. 2016; 49: 2080
• 2j Pons A, Poisson T, Pannecoucke X, Charette AE, Jubault P. Synthesis 2016; 48: 4060
• 2k Ganesh V, Chandrasekaran S. Synthesis 2016; 48: 4347
• 2l Pellissier H, Lattanzi A, Dalpozzo R. Asymmetric Cyclopropanation . In Asymmetric Synthesis of Three-Membered Rings . Wiley-VCH; Weinheim: 2017: 1
• 2m Bos M, Poisson T, Pannecoucke X, Charette AE, Jubault P. Chem. Eur. J. 2017; 23: 4950
• 2n Tomilov YV, Menchikov LG, Novikov RA, Ivanova OA, Trushkov IV. Russ. Chem. Rev. 2018; 87: 201
• 2o Martín-Heras V, Parra M, Tortosa A. Synthesis 2018; 50: 470
• 2p Roy A, Goswami SP, Sarkar A. Synth. Commun. 2018; 48: 2003
• 2q Wu W, Lin Z, Jiang H. Org. Biomol. Chem. 2018; 16: 7315
• 2r Herraiz AG, Suero MG. Synthesis 2019; 51: 2821
• 2s Allouche EM. D, Charette AB. Synthesis 2019; 51: 3947

For selected reviews on the reactivity of cyclopropane derivatives, see:
• 3a Reissig H.-U. Organic Synthesis via Cyclopropanes: Principles and Applications. In The Chemistry of the Cyclopropyl Group, Vol. 1. Patai S, Rappaport Z. Wiley; Chichester: 1987: 375
• 3b Verhé R, de Kimpe N. Synthesis and Reactivity of Electrophilic Cyclopropanes. In The Chemistry of the Cyclopropyl Group, Vol. 1. Patai S, Rappaport Z. Wiley; Chichester: 1987: 445
• 3c Boche G, Walborsky HM. Cyclopropyl Radicals, Anion Radicals and Anions . In The Chemistry of the Cyclopropyl Group, Vol. 1. Patai S, Rappaport Z. Wiley; Chichester: 1987: 701
• 3d Reissig H.-U, Zimmer R. Chem. Rev. 2003; 103: 1151
• 3e Carson CA, Kerr MA. Chem. Soc. Rev. 2009; 38: 3051
• 3f Davies HM. L, Denton JR. Chem. Soc. Rev. 2009; 38: 3061
• 3g Simone FD, Waser J. Synthesis 2009; 3353
• 3h Zhang D, Song H, Qin Y. Acc. Chem. Res. 2011; 44: 447
• 3i Tang P, Qin Y. Synthesis 2012; 2969
• 3j Schneider TF, Kaschel J, Werz DB. Angew. Chem. Int. Ed. 2014; 53: 5504
• 3k Kulinkovich OG. Cyclopropanes in Organic Synthesis . John Wiley & Sons; Hoboken: 2015
• 3l Wang L, Tang Y. Isr. J. Chem. 2016; 56: 463
• 3m Vicente R. Synthesis 2016; 48: 2343
• 3n Fumagalli G, Stanton S, Bower JF. Chem. Rev. 2017; 117: 9404
• 3o Ebner C, Carreira EM. Chem. Rev. 2017; 117: 11651

For selected reviews and book chapters on cyclopropane derivatives in natural products, see:
• 4a Liu H, Walsh CT. Biochemistry of the Cyclopropyl Group . In The Chemistry of the Cyclopropyl Group, Vol. 1. Patai S, Rappaport Z. Wiley; Chichester: 1987: 959
• 4b Donaldson WA. Tetrahedron 2001; 57: 8589
• 4c Wessjohann LA, Brandt W, Thiemann T. Chem. Rev. 2003; 103: 1625
• 4d Chen DY.-K, Pouwer RH, Richard J.-A. Chem. Soc. Rev. 2012; 41: 4631
• 4e Fan YY, Gao XH, Yue JM. Sci. China: Chem. 2016; 59: 1126
• 5 For selected review on cyclopropane derivatives in fragrances, see: Schröder F. Chem. Biodiversity 2014; 11: 1734

For selected reviews on cyclopropane derivatives in agrochemicals, see:
• 6a Faust R. Angew. Chem. Int. Ed. 2001; 40: 2251
• 6b Schleier JJ. III, Peterson RK. D. Pyrethrins and Pyrethroid Insecticides . In Green Trends in Insect Control . Lopez O, Fernandez-Bolanos J. Royal Society of Chemistry; Cambridge: 2011: 94
• 7a Salaün J. Cyclopropane Derivatives and their Diverse Biological Activities. In Topics in Current Chemistry, Vol. 207. de Meijere A. Springer; Heidelberg: 2000: 1
• 7b Marson CM. Chem. Soc. Rev. 2011; 40: 5514
• 7c Meanwell NA. J. Med. Chem. 2011; 54: 2529
• 7d Taylor RD, MacCoss M, Lawson AD. G. J. Med. Chem. 2014; 57: 5845
• 7e Talele TT. J. Med. Chem. 2016; 59: 8712

For pharmacological properties and synthesis of drospirenone, see:
• 8a Rapkin AJ, Winer SA. Expert Opin. Pharmacother 2007; 8: 989
• 8b Bandini M, Contento M, Garelli A, Monari M, Tolomelli A, Umani-Ronchi A, Andriolo E, Montorsi M. Synthesis 2008; 3801
• 8c Deng G, Huang Z, Zhao X, Li Z, Li Y, Jiang B. Chin. J. Chem. 2013; 31: 15

For pharmacological properties and synthesis of nevirapine, see:
• 9a Skoog MT, Hargrave KD, Miglietta JJ, Kopp EB, Merluzzi VJ. Med. Res. Rev. 1992; 12: 27
• 9b Kawalec P, Kryst J, Mikrut A, Pilc A. PLoS ONE 2013; 8: e76587
• 9c Patel UR, Proudfoot JR. J. Org. Chem. 1992; 57: 4023

For pharmacological properties and synthesis of milnacipran, see:
• 10a Bernstein CD, Albrecht KL, Marcus DA. Expert Opin. Pharmacother. 2013; 14: 905
• 10b Boyer P, Briley M. Drugs Today 1998; 34: 709
• 10c Doyle MP, Hu W. Adv. Synth. Catal. 2001; 343: 299

For pharmacological properties and synthesis of moxifloxacin, see:
• 11a Burkhardt O, Welte T. Expert Rev. Anti-Infect. Ther. 2009; 645
• 11b Seidel D, Conrad M, Brehmer P, Mohrs K, Petersen U. J. Labelled Compd. Radiopharm. 2000; 43: 795
• 11c Li GX, Lei WU, Qing QF. U, Tang Z, Zhang X. Sci. China Chem. 2013; 56: 307

For pharmacological properties and synthesis of montelukast, see:
• 12a Storms W. Expert Opin. Pharmacother. 2007; 8: 2173
• 12b Amlani S, Nadarajah T, McIvor RA. Expert Opin. Pharmacother. 2011; 12: 2119
• 12c Zhu GL, Zhang XD, Yang LJ, Xie JH, Che DQ, Zhou QL, Yan PC, Li YQ. Org. Process Res. Dev. 2016; 20: 81

For pharmacological properties and synthesis of abacavir, see:
• 13a Hervey PS, Perry CM. Drugs 2000; 60: 447
• 13b Greig SL, Deeks ED. Drugs 2015; 75: 503
• 13c Boyle GA, Edlin CD, Li Y, Liotta DC, Morgans GL, Musonda CC. Org. Biomol. Chem. 2012; 10: 1870
• 13d Thieme N, Breit B. Angew. Chem. Int. Ed. 2017; 56: 1520

For pharmacological properties and synthesis of efavirenz, see:
• 14a Bastos MM. P, Costa CC, Bezerra TC, Da Silva FC, Boechat N. Eur. J. Med. Chem. 2016; 108: 455
• 14b Zhang J, Wang Y. Curr. Org. Chem. 2017; 21: 2196
• 14c Kawai H, Kitayama T, Tokunaga E, Shibata N. Eur. J. Org. Chem. 2011; 5959
• 14d Griffiths GJ, Warm A. Org. Process Res. Dev. 2016; 20: 803

For pharmacological properties and synthesis of pitavastatin, see:
• 15a Corsini A, Ceska R. Curr. Med. Res. Opin. 2011; 27: 1551
• 15b Ohbayashi H. Drugs Today 2010; 46: 765
• 15c Fabris J, Gazić Smilović I, Časar Z. Synthesis 2012; 44: 1700
• 15d Fabris J, Časar Z, Gazić Smilović I, Črnugelj M. Synthesis 2014; 46: 2333
• 15e Časar Z. Top. Heterocycl. Chem. 2016; 44: 113

For pharmacological properties and synthesis of prasugrel, see:
• 16a Angiolillo DJ, Suryadevara S, Capranzano P, Bass TA. Expert Opin. Pharmacother. 2008; 9: 2893
• 16b Ahmad S, Storey RF. Curr. Pharm. Des. 2012; 18: 5240
• 16c Lhermusier T, Waksman R. Expert Opin. Pharmacother. 2015; 16: 585
• 16d Aalla S, Gilla G, Metil DS, Anumula RR, Vummenthala PR, Padi PR. Org. Process Res. Dev. 2012; 16: 240
• 16e Pan X.-H, Zhang Q.-H, Liu F. Tetrahedron Lett. 2012; 53: 5364

For pharmacological properties and synthesis of besifloxacin, see:
• 17a Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. Antimicrob. Agents Chemother. 2009; 53: 3552
• 17b Carter NJ, Scott LJ. Drugs 2010; 70: 83
• 17c Mah FS, Sanfilippo CM. Ophthalmol. Ther. 2016; 5: 1
• 17d Harms AE. WO 2008091752, 2008 ; Chem. Abstr. 2008, 149, 200799.

For pharmacological properties and synthesis of saxagliptin, see:
• 18a Dhillon S. Drugs 2015; 75: 1783
• 18b Savage SA, Jones GS, Kolotuchin S, Ramrattan SA, Vu T, Waltermire RE. Org. Process Res. Dev. 2009; 13: 1169

For pharmacological properties and synthesis of ticagrelor, see:
• 19a Htun WW, Steinhubl SR. Expert Opin. Pharmacother. 2013; 14: 237
• 19b Al-Salama ZT, Keating GM, Keam SJ. Drugs 2017; 77: 2025
• 19c Wen H.-J, Chen Q, Zheng G.-J. Chin. Chem. Lett. 2015; 26: 1431
• 19d Włodarczyk J, Wolan A, Rakowiecki M, Bosiak MJ, Budny M. Tetrahedron Lett. 2015; 56: 6093
• 19e Hernandez KE, Renata H, Lewis RD, Kan SB. J, Zhang C, Forte J, Rozzell D, McIntosh JA, Arnold FH. ACS Catal. 2016; 6: 7810
• 19f Hugentobler KG, Sharif H, Rasparini M, Heatha RS, Turner NJ. Org. Biomol. Chem. 2016; 14: 8064
• 19g Singh M, Krishnen H, Kumar Neelam U, Charugondla K, Gilla G, Holt-Tiffinb K, Bandichhor R. RSC Adv. 2016; 6: 35086
• 19h Hugentobler KG, Rasparini M, Thompson LA, Jolley KE, Blacker AJ, Turner NJ. Org. Process Res. Dev. 2017; 21: 195
• 19i Guo X, Tang J.-W, Yang J.-T, Ni G.-W, Zhang F.-L, Chen S.-X. Org. Process Res. Dev. 2017; 21: 1595

For pharmacological properties and synthesis of boceprevir, see:
• 20a Garnock-Jones KP. Drugs 2012; 72: 2431
• 20b Morris WJ, Muppalla KK, Cowden C, Ball RG. J. Org. Chem. 2013; 78: 706
• 20c Bhalerao DS, Arkala AK. R, Madhavi YV, Nagaraju M, Gade SR, Kumar UK. S, Bandichhor R, Dahanukar VH. Org. Process Res. Dev. 2015; 19: 1559

For pharmacological properties and synthesis of telaprevir, see:
• 21a Perry CM. Drugs 2012; 72: 619
• 21b Znabet A, Polak MM, Janssen E, de Kanter FJ. J, Turner NJ, Orru RV. A, Ruijter E. Chem. Commun. 2010; 46: 7918
• 21c Tanoury GJ, Chen M, Dong Y, Forslund R, Jurkauskas V, Jones A, Belmont D. Org. Process Res. Dev. 2014; 18: 1234
• 21d Moni L, Banfi L, Basso A, Carcone L, Rasparini M, Riva R. J. Org. Chem. 2015; 80: 3411
• 22 Sales data were obtained from the IQVIA™ Analytics Link database.
• 23a Mullard A. Nat. Rev. Drug Discovery 2013; 12: 87
• 23b Mullard A. Nat. Rev. Drug Discovery 2014; 13: 85
• 23c Mullard A. Nat. Rev. Drug Discovery 2015; 14: 77
• 23d Mullard A. Nat. Rev. Drug Discovery 2016; 15: 73
• 23e Mullard A. Nat. Rev. Drug Discovery 2017; 16: 73
• 23f Mullard A. Nat. Rev. Drug Discovery 2018; 17: 81
• 23g Mullard A. Nat. Rev. Drug Discovery 2019; 18: 85

For pharmacological properties and synthesis of cabozantinib, see:
• 24a Roy S, Narang BK, Rastogi SK, Rawal RK. Anti-Cancer Agents Med. Chem. 2015; 15: 37
• 24b Bannen LC, Chan DS.-M, Chen J, Dalrymple LE, Forsyth TP, Huynh TP, Jammalamadaka V, Khoury RG, Leahy JW, Mac MB, Mann G, Mann LW, Nuss JM, Parks JJ, Takeuchi CS, Wang Y, Xu W. WO 2005030140, 2005 ; Chem. Abstr. 2005, 142, 373856.
• 24c Dragan A, Kubczyk TM, Rowley JH, Sproules S, Tomkinson NC. O. Org. Lett. 2015; 17: 261
• 24d St Clair Brown A, Lamb P, Gallagher WP. WO 2010083414, 2011 ; Chem. Abstr. 2010, 153, 204211.
• 24e Laus G, Schreiner E, Nerdinger S, Kahlenberg V, Wurst K, Vergeiner S, Schottenberger H. Heterocycles 2016; 93: 323
• 24f Fang R, Wang B, Zhao Z, Yin L, Wang H, Xu J. Org. Prep. Proced. Int. 2019; 51: 381
• 24g Lien VT, Klaveness J, Olberg DE. J. Labelled Compd. Radiopharm. 2018; 61: 11

For pharmacological properties and synthesis of trametinib, see:
• 25a Salama AK. S, Kim KB. Expert Opin. Pharmacother. 2013; 14: 619
• 25b Chopra N, Nathan PD. Expert Rev. Anticancer Ther. 2015; 15: 749
• 25c Suo Z, Sun Q, Yang H, Tang P, Gan R, Xiong X, Li H. RSC Adv. 2018; 8: 4742
• 25d Sakai T, Kawasaki H, Abe H, Hayakawa K, Iida T, Kikuchi S, Yamaguchi T, Nanayama T, Kurachi H, Tamaru M, Hori Y, Takahashi M, Yoshida T. WO 2005121142, 2005 ; Chem. Abstr. 2005, 144, 64334.
• 25e Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, Sakamoto J, Matsumoto N, Miura T, Matsumura K, Seki N, Inaba T, Kawasaki H, Yamaguchi T, Kakefuda R, Nanayama T, Kurachi H, Hori Y, Yoshida T, Kakegawa J, Watanabe Y, Gilmartin AG, Richter MC, Moss KG, Laquerre SG. ACS Med. Chem. Lett. 2011; 2: 320

For pharmacological properties and synthesis of simeprevir, see:
• 26a Vaidya A, Perry CM. Drugs 2013; 73: 2093
• 26b You DM, Pockros PJ. Expert Opin. Pharmacother. 2013; 14: 2581
• 26c Sanford M. Drugs 2015; 75: 183
• 26d Raboisson PJ.-M. B, De Kock HA, Hu L, Vendeville SM. H, Tahri A, Surleraux DL. N. G, Simmen KA, Nilsson KM, Samuelsson BB, Rosenquist AA. K, Ivanov V, Pelcman M, Belfrage AK. G. L, Johansson P.-OM. WO 2007014926, 2007 ; Chem. Abstr. 2007, 146, 206646.
• 26e Raboisson P, de Kock H, Rosenquist Å, Nilsson M, Salvador-Oden L, Lin T.-I, Roue N, Ivanov V, Wähling H, Wickström K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K. Bioorg. Med. Chem. Lett. 2008; 18: 4853
• 26f Rosenquist Å, Samuelsson B, Johansson P.-O, Cummings MD, Lenz O, Raboisson P, Simmen K, Vendeville S, de Kock H, Nilsson M, Horvath A, Kalmeijer R, de la Rosa G, Beumont-Mauviel M. J. Med. Chem. 2014; 57: 1673
• 26g Sato T, Izawa K, Aceña JL, Liu H, Soloshonok VA. Eur. J. Org. Chem. 2016; 2757
• 26h Kawashima A, Xie C, Mei H, Takeda R, Kawamura A, Sato T, Moriwaki H, Izawa K, Han J, Aceña JL, Soloshonok VA. RSC Adv. 2015; 5: 1051
• 26i Horvath A, Depre DP. M, Ormerod DJ. WO 2008092955, 2008 ; Chem. Abstr. 2008, 149, 224566.
• 26j Horvath A, Ormerod DJ, Depre DP. M, Cerpentier V. WO 2010072742, 2010 ; Chem. Abstr. 2010, 153, 145703.
• 26k Ormerod DJ, Depre DP. M, Horvath A. WO 2011113859, 2011 ; Chem. Abstr. 2011, 155, 434300.
• 26l Depre DP. M, Ormerod DJ, Horvath A. WO 2013041655, 2013 ; Chem. Abstr. 2013, 158, 503901.
• 26m Rádl S, Rezková H, Obadalová I, Srbek J, Břicháč J, Pekárek T. Synthesis 2014; 46: 899
• 26n Horváth A, Depré D, Vermeulen WA. A, Wuyts SL, Harutyunyan SR, Binot G, Cuypers J, Couck W, Van Den Heuvel D. J. Org. Chem. 2019; 84: 4932
• 27 Tsantrizos YS. Top. Heterocycl. Chem. 2016; 44: 89

For pharmacological properties and synthesis of ledipasvir, see:
• 28a Kumari R, Nguyen MH. Expert Opin. Pharmacother. 2015; 16: 739
• 28b Guo H, Kato D, Kirschberg TA, Liu H, Link JO, Mitchell ML, Parrish JP, Squires N, Sun J, Taylor J, Bacon EM, Canales E, Cho A, Cottell JJ, Desai MC, Halcomb RL, Krygowski ES, Lazerwith SE, Liu Q, Mackman R, Pyun H.-J, Saugier JH, Trenkle JD, Tse WC, Vivian RW, Schroeder SD, Watkins WJ, Xu L, Yang Z.-Y, Kellar T, Sheng X, Clarke MO. H, Chou C.-H, Graupe M, Jin H, Mcfadden R, Mish MR, Metobo SE, Phillips BW, Venkataramani C. WO 2010132601, 2010 ; Chem. Abstr. 2010, 153, 643864.
• 28c Scott RW, Vitale JP, Matthews KS, Teresk MG, Formella A, Evans JW. WO 2013184702, 2013 ; Chem. Abstr. 2013, 160, 34090.
• 28d Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Keller T, Yang Z.-Y, Yang C, Matles M, Wang Y, Wang K, Cheng G, Tian Y, Mogalian E, Mondou E, Cornpropst M, Perry J, Desai MC. J. Med. Chem. 2014; 57: 2033

For pharmacological properties and synthesis of olaparib, see:
• 29a McLachlan J, Banerjee S. Expert Opin. Pharmacother. 2016; 17: 995
• 29b Gunderson CC, Moore KN. Future Oncol. 2015; 11: 747
• 29c Martin NM. B, Smith GC. M, Jackson SP, Loh VM. Jr, Cockcroft X.-LF, Matthews IT. W, Menear KA, Kerrigan F, Ashworth A. WO 2004080976, 2004 ; Chem. Abstr. 2004, 141, 296034.
• 29d Menear KA, Ottridge AP, Londesbrough DJ, Hallett MR, Mullholland KR, Pittam JD, Laffan DD. P, Ashworth IW, Jones MF, Cherryman JH. WO 2008047082, 2008 ; Chem. Abstr. 2008, 148, 495983.
• 29e Quigley KA, Still EJ, Chyall LJ. WO 2009050469, 2009 ; Chem. Abstr. 2009, 167, 252261.
• 29f Menear KA, Adcock C, Boulter R, Cockcroft X-l, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM. Jr, Matthews IT. W, Moore S, O’Connor MJ, Smith GC. M, Martin NM. B. J. Med. Chem. 2008; 51: 6581
• 29g Modvig A, Andersen TL, Taaning RH, Lindhardt AT, Skrydstrup T. J. Org. Chem. 2014; 79: 5861
• 29h Collin HP, Reis WJ, Nielsen DU, Lindhardt AT, Valle MS, Freitas RP, Skrydstrup T. Org. Lett. 2019; 21: 5775

For pharmacological properties and synthesis of tasimelteon, see:
• 30a Lankford DA. Expert Opin. Invest. Drugs 2011; 20: 987
• 30b Dhillon S, Clarke M. Drugs 2014; 74: 505
• 30c Eissenstat MA, Bell MR, D’Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM, Wetzel JR, Alexander MD, Weaver JD, Haycock DA, Luttinger DA, Casiano FM, Chippari SM, Kuster JE, Stevenson JI, Ward SJ. J. Med. Chem. 1995; 38: 3094
• 30d Catt JD, Johnson G, Keavy DJ, Mattson RJ, Parker MF, Takaki KS, Yevich JP. WO 9825606, 1998 ; Chem. Abstr. 1998, 129, 81535.
• 30e Phadke D, Platt NM. WO 2015123389, 2015 ; Chem. Abstr. 2015, 163, 331231.
• 30f Pereira DE, Aumiller W, Dagger R. US 2007270593, 2007 ; Chem. Abstr. 2007, 147, 541998.
• 30g Singh AK, Rao MN, Simpson JH, Li W.-S, Thornton JE, Kuehner DE, Kacsur DJ. Org. Process Res. Dev. 2002; 6: 618
• 30h Prasad JS, Vu T, Totleben MJ, Crispino GA, Kacsur DJ, Swaminathan S, Thornton JE, Fritz A, Singh AK. Org. Process Res. Dev. 2003; 7: 821
• 30i Mi S, Sun X, Wu C, Zhang X. J. Chem. Res. 2016; 40: 667
• 30j Bajaj P, Sreenilayam G, Tyagi V, Fasan R. Angew. Chem. Int. Ed. 2016; 55: 16110
• 30k Wang W, Meng X, Zhu J, Zhang X. Synth. Commun. 2019; 49: 129
• 30l Li X.-A, Yue L, Zhu J, Ren H, Zhang H, Hu D.-y, Han G, Feng J, Nan Z.-d. Tetrahedron Lett. 2019; 60: 1986

For pharmacological properties and synthesis of finafloxacin, see:
• 31a Vasiliou SM, Vicente M. Drugs Future 2009; 34: 451
• 31b McKeage K. Drugs 2015; 75: 687
• 31c Bartoletti R, Cai T, Perletti G, Wagenlehner FM. E, Bjerklund Johansen TE. Expert Opin. Invest. Drugs 2015; 24: 957
• 31d Matzke M, Petersen U, Jaetsch T, Bartel S, Schenke T, Himmler T, Baasner B, Werling H.-O, Schaller K, Labischinski H. WO 9826779, 1998 ; Chem. Abstr. 1998, 129, 81719.
• 31e Hong J, Zhang Z, Lei H, Cheng H, Hu Y, Yang W, Liang Y, Das D, Chen S.-H, Li G. Tetrahedron Lett. 2009; 50: 2525
• 31f Walker DP, Strohbach JW, McGlynn MA, Lu H.-F. J. Heterocycl. Chem. 2010; 47: 1095

For pharmacological properties and synthesis of paritaprevir, see:
• 32a Carrion AF, Gutierrez J, Martin P. Expert Opin. Pharmacother. 2014; 15: 711
• 32b Gentile I, Borgia F, Buonomo AR, Zappulo E, Castaldo G, Borgia G. Curr. Med. Chem. 2014; 21: 3261
• 32c Minaei AA, Kowdley KV. Expert Opin. Pharmacother. 2015; 16: 929
• 32d Ku Y, McDaniel KF, Chen H.-J, Shanley JP, Kempf DJ, Grampovnik DJ, Sun Y, Liu D, Gai Y, Or YS, Wagaw SH, Engstrom K, Grieme T, Sheikh A, Mei J. WO 2010030359, 2010 ; Chem. Abstr. 2010, 152, 358302.
• 32e Park J, Moore JC, Xu F. Org. Process Res. Dev. 2016; 20: 76

For pharmacological properties and synthesis of lenvatinib, see:
• 33a Wu P, Nielsen TE, Clausen MH. Trends Pharmacol. Sci. 2015; 36: 422
• 33b Okamoto K, Ikemori-Kawada M, Jestel A, von König K, Funahashi Y, Matsushima T, Tsuruoka A, Inoue A, Matsui J. ACS Med. Chem. Lett. 2015; 6: 89
• 33c Costa R, Carneiro B, Chandra S, Pai S, Chae YK, Kaplan J, Garrett H, Agulnik M, Kopp P. Drug Des., Dev. Ther. 2016; 10: 873
• 33d Funahashi Y, Tsuruoka A, Matsukura M, Haneda T, Fukuda Y, Kamata J, Takahashi K, Matsushima T, Miyazaki K, Nomoto K, Watanabe T, Obaishi H, Yamaguchi A, Suzuki S, Nakamura K, Mimura F, Yamamoto Y, Matsui J, Matsui K, Yoshiba T, Suzuki Y, Arimoto I. WO 02032872, 2002 ; Chem. Abstr. 2002, 136, 340689.
• 33e Naito T, Yoshizawa K. WO 2005044788, 2005 ; Chem. Abstr. 2005, 142, 481959.

For pharmacological properties and synthesis of lumacaftor, see:
• 34a Van Goor F, Hadida S, Grootenhuis PD. J, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 18843
• 34b Kuk K, Taylor-Cousar JL. Ther. Adv. Respir. Dis. 2015; 9: 313
• 34c Deeks ED. Drugs 2016; 76: 1191
• 34d Hadida Ruah S, Hamilton M, Miller M, Grootenhuis PD. J, Bear B, Mccarthy J, Zhou J. WO 2007056341, 2007 ; Chem. Abstr. 2007, 146, 521690.
• 34e Siesel D. WO 2009076142, 2009 ; Chem. Abstr. 2009, 151, 56833.
• 34f Doiron JE, Le CA, Ody BK, Brace JB, Post SJ, Thacker NL, Hill HM, Breton GW, Mulder MJ, Chang S, Bridges TM, Tang L, Wang W, Rowe SM, Aller SG, Turlington M. Chem. Eur. J. 2019; 25: 3662
• 34g Siesel D. WO 2010138484, 2010 ; Chem. Abstr. 2010, 153, 643460.

For pharmacological properties and synthesis of lesinurad, see:
• 35a Hoy SM. Drugs 2016; 76: 509
• 35b Wang J, Zeng W, Li S, Shen L, Gu Z, Zhang Y, Li J, Chen S, Jia X. ACS Med. Chem. Lett. 2017; 8: 299
• 35c Girardet J.-L, Koh Y.-H, De la Rosa M, Gunic E, Hong Z, Lang S, Kim HW. WO 2006026356, 2006 ; Chem. Abstr. 2006, 144, 292762.
• 35d Quart BD, Girardet J.-L, Gunic E, Yeh L.-T. WO 2009070740, 2009 ; Chem. Abstr. 2009, 151, 8507.
• 35e Wang P, Li P, Gu X. WO 2015054960, 2015 ; Chem. Abstr. 2015, 162, 564086.
• 35f Meng Q, Zhao T, Kang D, Huang B, Zhan P, Liu X. Chem. Cent. J. 2017; 11: 86 , DOI: 10.1186s13065017-0316-y
• 35g Halama A, Stach J, Rádl S, Benediktová K. Org. Process Res. Dev. 2018; 22: 1861

For pharmacological properties and synthesis of grazoprevir, see:
• 36a Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. Expert Opin. Invest. Drugs 2014; 23: 719
• 36b Majumdar A, Gilliam BL. Drugs Future 2016; 41: 85
• 36c Harper S, Summa V, Liverton NJ, McCauley JA. WO 2010011566, 2010 ; Chem. Abstr. 2010, 152, 192450.
• 36d Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, Koch U, Petrocchi A, Holloway MK, Butcher JW, Romano JJ, Bush KJ, Gilbert KF, McIntyre CJ, Nguyen KT, Nizi E, Carroll SS, Ludmerer SW, Burlein C, DiMuzio JM, Graham DJ, McHale CM, Stahlhut MW, Olsen DB, Monteagudo E, Cianetti S, Giuliano C, Pucci V, Trainor N, Fandozzi CM, Rowley M, Coleman PJ, Vacca JP, Summa V, Liverton NJ. ACS Med. Chem. Lett. 2012; 3: 332
• 36e Zhong YL, Yasuda N, Li H, McLaughlin M, Tschaen D. Top. Curr. Chem. 2016; 374: 77
• 36f Bassan EM, Baxter CA, Beutner GL, Emerson KM, Fleitz FJ, Johnson S, Keen S, Kim MM, Kuethe JT, Leonard WR, Mullens PR, Muzzio DJ, Roberge C, Yasuda N. Org. Process Res. Dev. 2012; 16: 87
• 36g Kuethe J, Zhong Y.-L, Yasuda N, Beutner G, Linn K, Kim M, Marcune B, Dreher SD, Humphrey G, Pei T. Org. Lett. 2013; 15: 4174
• 36h Williams M, McLaughlin M, Kong J, Jin Y. WO 2015095430, 2015 ; Chem. Abstr. 2015, 163, 161439.
• 36i Williams MJ, Kong J, Chung CK, Brunskill A, Campeau LC, McLaughlin M. Org. Lett. 2016; 18: 1952
• 36j Xu F, Zhong Y.-L, Li H, Qi J, Desmond R, Song ZJ, Park J, Wang T, Truppo M, Humphrey GR, Ruck RT. Org. Lett. 2017; 19: 5880
• 36k Xu F, Kim J, Waldman J, Wang T, Devine P. Org. Lett. 2018; 20: 7261
• 36l Kim T, Kassim AM, Botejue A, Zhang C, Forte J, Rozzell D, Huffman MA, Devine PN, McIntosh JA. ChemBioChem 2019; 20: 1129

For pharmacological properties and synthesis of glecaprevir, see:
• 37a Lamb YN. Drugs 2017; 77: 1797
• 37b Carrion AF, Martin P. Expert Opin. Pharmacother. 2018; 19: 413
• 37c Wang AX, Zheng BZ, D’Andrea S, Zhao Q, Scola PM. WO 2008064066, 2008 ; Chem. Abstr. 2008, 149, 10287.
• 37d Bjornson K, Karki KK, Link JO, Pyun H.-J, Schrier AJ, Stevens KL, Taylor JG, Vivian RW, Zablocki J, Zipfel S. WO 2014145095, 2014 ; Chem. Abstr. 2014, 161, 505380.
• 37e Or YS, Ma J, Wang G, Long J, Wang B. US 20120070416, 2012 ; Chem. Abstr. 2012, 156, 421825.
• 37f Cink RD, Lukin K, Bishop RD, Zhao G, Pelc MJ, Towne TB, Gates BD, Ravn MM, Hill DR, Ding C, Cullen SC, Mei J, Leanna MR, Henle J, Napolitano JG, Nere N, Chen S, Sheikh AY, Kallemeyn JM. Org. Process Res. Dev. 2020; 24: 183

For pharmacological properties and synthesis of ozenoxacin, see:
• 38a Yamakawa T, Mitsuyama J, Hayashi K. J. Antimicrob. Chemother. 2002; 49: 455
• 38b Canton R, Chouinard L, Tarragó C. Future Microbiol. 2018; 13 (6s): 1
• 38c Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, Cantón R. Expert Rev. Anti-Infect. Ther. 2019; 17: 159
• 38d Hayashi K, Kito T, Mitsuyama J, Yamakawa T, Kuroda H, Kawafuchi H. WO 9951588, 1999 ; Chem. Abstr. 1999, 131, 271816.

For pharmacological properties and synthesis of voxilaprevir, see:
• 39a Heo Y.-A, Deeks ED. Drugs 2018; 78: 577
• 39b Cory TJ, Mu Y, Gong Y, Kodidela S, Kumar S. Expert Opin. Pharmacother. 2018; 19: 749
• 39c Taylor JG, Zipfel S, Ramey K, Vivian R, Schrier A, Karki KK, Katana A, Kato D, Kobayashi T, Martinez R, Sangi M, Siegel D, Tran CV, Yang Z.-Y, Zablocki J, Yang CY, Wang Y, Wang K, Chan K, Barauskas O, Cheng G, Jin D, Schultz BE, Appleby T, Villaseñord AG, Link O. Bioorg. Med. Chem. Lett. 2019; 29: 2428
• 39d Chabaud P, Pèpe G, Courcambeck J, Camplo M. Tetrahedron 2005; 61: 3725
• 39e Bjornson K, Canales E, Cottell JJ, Karki KK, Katana AA, Kato D, Kobayashi T, Link JO, Martinez R, Phillips BW, Pyun H.-J, Sangi M, Schrier AJ, Siegel D, Taylor JG, Tran CV, Trejo Martin TA, Vivian RW, Yang Z.-Y, Zablocki J, Zipfel S. WO 2014008285, 2014 ; Chem. Abstr. 2014, 160, 190332.
• 39f Cagulada A, Chan J, Chan L, Colby DA, Karki KK, Kato D, Keaton KA, Kondapally S, Levins C, Littke A, Martinez R, Pcion D, Reynolds T, Ross B, Sangi M, Schrier AJ, Seng P, Siegel D, Shapiro N, Tang D, Taylor JG, Tripp J, Waltman AW, Yu L. US 20150175626, 2015 ; Chem. Abstr. 2015, 163, 174754.

For pharmacological properties and synthesis of naldemedine, see:
• 40a Brower V. Lancet Oncol. 2017; 18: e306
• 40b Markham A. Drugs 2017; 77: 923
• 40c Fujii H, Hirano N, Uchiro H, Kawamura K, Nagase H. Chem. Pharm. Bull. 2004; 52: 747
• 40d Dongbang S, Pedersen B, Ellman JA. Chem. Sci. 2019; 10: 535
• 40e Endoma-Arias MA. A, Cox DP, Hudlicky T. Adv. Synth. Catal. 2013; 355: 1869
• 40f Inagaki M, Hara S.-I, Haga N, Tamura Y, Goto Y, Hasegawa T. WO 2006126529, 2006 ; Chem. Abstr. 2006, 146, 27969.
• 40g Inagaki M, Kume M, Tamura Y, Hara S, Goto Y, Haga N, Hasegawa T, Nakamura T, Koike K, Oonishi S, Kanemasa T, Kai H. Bioorg. Med. Chem. Lett. 2019; 29: 73
• 40h Tamura Y, Noguchi K, Inagaki M, Morimoto K, Haga N, Oda S, Omura S. US 20130231485, 2013 ; Chem. Abstr. 2013, 156, 638276.

For synthesis of tezacaftor, see:
• 41a Sala MA, Jain M. Expert Rev. Respir. Med. 2018; 12: 725
• 41b Tanoury GJ, Harrison C, Littler BJ, Rose PJ, Hughes RM, Jung YC, Siesel DA, Belmont DT. WO 2011133751, 2011 ; Chem. Abstr. 2011, 155, 588925.

For synthesis of tecovirimat, see:
• 42a Hoy SM. Drugs 2018; 78: 1377
• 42b Bolken TC, Hruby DE. Drugs Today 2010; 46: 109
• 42c Jordan R, Bailey TR, Rippin SR, Dai D. WO 2008079159, 2008 ; Chem. Abstr. 2008, 148, 121578.
• 42d Dai D. WO 2014028545, 2014 ; Chem. Abstr. 2014, 160, 356312.

For selected reviews on fluorinated drugs, see:
• 43a Wang J, Sánchez-Roselló M, Aceña JL, del Pozo C, Sorochinsky AE, Fustero S, Soloshonok VA, Liu H. Chem. Rev. 2014; 114: 2432
• 43b Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. J. Med. Chem. 2015; 58: 8315
• 43c Zhou Y, Wang J, Gu J, Wang S, Zhu W, Aceña JL, Soloshonok VA, Izawa K, Liu H. Chem. Rev. 2016; 116: 422
• 43d Meanwell NA. J. Med. Chem. 2018; 61: 5822
• 44a de la Torre BG, Albericio F. Molecules 2020; 25: 745
• 44b Mullard A. Nat. Rev. Drug Discovery 2020; 19: 79
• 45 Hoyer D, Jacobson LH. Drugs Future 2018; 43: 715
• 46a Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR. Antimicrob. Agents Chemother. 2018; 62: e00280-18
• 46b Wang Q, Yang F, Du H, Hossain MM, Bennett D, Grubisha DS. Tetrahedron: Asymmetry 1998; 9: 3971